Ag平台·(中国区)集团官方网站

Primary results from the phase III ALTN-AK105-III-02 study: Anlotinib plus penpulimab versus sorafenib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC)

Interim analysis results from a phase II study of adjuvant penpulimab in very high-risk clear cell renal cell carcinoma

A prospective exploratory clinical study of penpulimab plus anlotinib as first-line treatment for locally advanced or metastatic urothelial carcinoma

Penpulimab plus gemcitabine incombination with cisplatin or anlotinib as first-line treatment for metastatic nasopharyngeal carcinoma (MNPC):A phase II study.

Penpulimab plus anlotinib in patients with recurrent or metastatic head and neck squamous cell carcinoma after the failure of first-line platinum-based chemotherapy: A single-arm, multicenter, phase 2 study.

Efficacy and safety of Penpulimab plus Anlotinib in recurrent/metastatic head and neck squamous cell carcinoma, a phase Ⅱ study

A phase ll study of Penpulimab, an lgG1 anti-PD-1 antibody, in patients with relapsed or refractory classical Hodgkin lymphoma (cHL)

Penpulimab-based combination neoadjuvant/adjuvant therapy for patients with resectable locally advanced non-small cell lung cancer: a phase Ⅱ clinical study (ALTER-L043)

Penpulimab plus anlotinib as second-line treatment for the small cell lung cancer after failure of platinum-based systemic chemotherapy.

Clinical activity and safety of Penpulimab (Anti-PD-1) with Anlotinib as First-line Therapy for Advanced Hepatocellular Carcinoma (HCC)

Efficacy and safety of penpulimab (AK105), a new generation anti-programmed cell death-1 (PD-1) antibody, in upper gastrointestinal cancers

 Penpulimab, an IgG1 anti-PD-1 antibody with Fc-engineering to eliminate effector functions and with unique epitope and binding properties.

Zheng Y, Mislang ARA, Coward J, et al. Penpulimab, an anti-PD1 IgG1 antibody in the treatment of advanced or metastatic upper gastrointestinal cancers 

Song Y, Zhou K, Jin C, et al. Penpulimab for Relapsed or Refractory Classical Hodgkin Lymphoma: A Multicenter, Single-Arm, Pivotal Phase I/II Trial (AK105-201). 

Tao Y, Han J, Li Y. Autoimmune hemolytic anemia in patients with relapsed Hodgkin's lymphoma after treatment with penpulimab, a monoclonal antibody against programmed death receptor-1. 

Zhang Z, Li Y, Dong Y, et al. Successful Treatment of a Patient With Multiple-Line Relapsed Extensive-Stage Small-Cell Lung Cancer Receiving Penpulimab Combined With Anlotinib: A Case Report. 

Han C, Ye S, Hu C, et al. Clinical Activity and Safety of Penpulimab (Anti-PD-1) With Anlotinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: An Open-Label, Multicenter, Phase Ib/II Trial (AK105-203).

Huang Z, Pang X, Zhong T, et al. Penpulimab, an Fc-Engineered IgG1 Anti-PD-1 Antibody, With Improved Efficacy and Low Incidence of Immune-Related Adverse Events.